Alligator Bioscience AB : - Major shareholders and board members transfer subscription rights free of charge to qualified investors

The Board of Directors of Alligator Bioscience AB (publ) ('Alligator' or 'the Company') decided on 15 December 2020, with the support of the authorization from the Annual General Meeting on 5 May 2020, to carry out a new issue of shares with preferential rights for the Company's existing shareholders of approximately SEK 86 million.

In connection with the Rights Issue, the Company's second largest shareholder, Sunstone Life Science Ventures Fund II K / S, and board member Carl Borrebaeck, at the request of qualified investors and in consultation with the Company's financial advisor Redeye, transferred 6,959,318 subscription rights, corresponding to approximately 8.4 MSEK or 10 percent of the Rights Issue.

Alligator's second largest shareholders, Sunstone Life Science Ventures Fund II K / S, and board member Carl Borrebaeck, who before the Rights Issue own approximately 8 and 2 percent of the total number of shares in the Company, respectively, have at the request of qualified investors and in consultation with the Company's financial advisers Redeye transferred 5,758,485 and 1,200,833 subscription rights, respectively, to which they were allotted within the framework of the Rights Issue. Through application forms, the investors have undertaken to subscribe for shares in the Rights Issue to a total value of approximately SEK 8.4 million, corresponding to approximately 10 percent of the Rights Issue. The transfers of the subscription rights have taken place free of charge.

Advisor

Redeye AB is the financial advisor, Setterwalls Advokatbyra AB is the legal advisor and Aktieinvest FK AB acts as an issuing institution in connection with the Rights Issue.

Contact:

Per Norlen

Tel: [phone]

Email: [e-mail]

About Alligator Bioscience AB

Alligator Bioscience is a public Swedish biotechnology company that develops tumor-targeted immunotherapies for cancer. Alligator's project portfolio focuses on the two priority drug candidates ATOR-1017 and mitazalimab. In addition, two projects are conducted through collaboration agreements; ALG.APV-527 in co-development with Aptevo Therapeutics Inc. and AC101 in clinical development through Shanghai Henlius Inc. The company has also recently developed a new concept for patient-specific immunotherapy, Neo-X-Prime. Alligator's shares are traded on Nasdaq Stockholm under the ticker 'ATORX'. The head office is located at Medicon Village in Lund, Sweden.

(C) 2021 Electronic News Publishing, source ENP Newswire